

HOTLINE: Effective August 19, 2019

New Test 3001764 Pancreatitis (SPINKI) Deletion/Duplication SPINK1 DD Image: Patient History for Pancreatitis (SPINKI) Del/Dup Image: Patient History for Pancreatitis (SPINKI) Del/Dup Additional Technical Information Methodology: Multiplex Ligation-dependent Probe Amplification Multiplex Ligation-dependent Probe Amplification

 Specimen Required:
 Collect:
 Lavender (K2EDTA), Pink (K2EDTA), or Yellow (ACD Solution A or B).
 Specimen Preparation:
 Transport 3 mL whole blood. (Min: 2 mL)
 Storage/Transport Temperature:
 Refrigerated.
 Stability (collection to initiation of testing):
 Ambient: 1 week; Refrigerated:
 1 month; Frozen: 6 months

Reference Interval: By Report

Interpretive Data:

Performed:

Reported:

Background Information for Pancreatitis (SPINK1) Deletion/Duplication:

Characteristics: Hereditary pancreatitis typically presents with recurrent episodes of pancreatic inflammation, abdominal pain, nausea, and vomiting. Ultimately, this evolves into chronic pancreatitis resulting in permanent pancreatic damage.

Epidemiology: Incidence of chronic pancreatitis is 5-12 in 100,000 per year and prevalence is approximately 50 in 100,000.

Inheritance of SPINK1-related pancreatitis: Autosomal dominant.

Penetrance: Variable.

Cause: Pathogenic variants in SPINK1, PRSS1, CFTR, CASR, CTRC, CPA1 and CLDN2 genes are associated with pancreatitis.

Clinical Sensitivity: 6 percent of hereditary pancreatitis is caused by pathogenic SPINK1 copy number variants.

Methodology: Multiplex ligation-dependent probe amplification (MLPA)

Analytical Sensitivity and Specificity: 99 percent.

Varies

12-14 days

Limitations: Diagnostic errors can occur due to rare sequence variations. Single base pair substitutions, small deletions/duplications, regulatory region and deep intronic variants will not be detected. Deletion/duplication breakpoints will not be determined. Variants in genes other than *SPINK1* will not be detected.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online at www.aruplab.com. See Compliance Statement C: www.aruplab.com/CS

CPT Code(s): 81479

New York DOH approval pending. Call for status update.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.